Corilagin decreases insulin resistance in polycystic ovary syndrome rat model through regulating AMPK/GSK3β pathway

科里拉京通过调控AMPK/GSK3β通路改善多囊卵巢综合征大鼠胰岛素抵抗

阅读:7
作者:Beili Lv, Xinrong Li, Haiyan Wang

Background

This study aims to explore the effects of Corilagin on insulin resistance (IR) of polycystic ovary syndrome (PCOS) and the underlying mechanisms.

Conclusions

The present research reported the protective effects of Corilagin on PCOS, and demonstrated the protection effect was related to decreasing IR through regulating AMPK/GSK3β pathway.

Methods

The PCOS rat model was established by subcutaneously injected with dehydroepiandrosterone (DHEA) of 6 mg/kg/day. Body weight and ovary weight were recorded. Serum glucose and insulin concentration were analyzed with commercial kits. The expression of adenosine monophosphate-activated protein kinase (AMPK) and glycogen synthase kinase 3β (GSK3β) was detected by Western blot.

Results

The results showed that DHEA could induce ovarian dysfunction of rats and Corilagin alleviated DHEA-induced ovarian dysfunction. Corilagin reduced DHEA-induced increase of serum glucose and insulin concentration. Corilagin increased the expression level of p-AMPK/AMPK and p-GSK3β/GSK3β of rat ovarian induced by DHEA. Conclusions: The present research reported the protective effects of Corilagin on PCOS, and demonstrated the protection effect was related to decreasing IR through regulating AMPK/GSK3β pathway.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。